Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022

Rhea-AI Summary

Biofrontera Inc. (Nasdaq: BFRI) will announce its financial results for Q1 2022 on May 13, 2022, prior to U.S. market opening. A conference call is scheduled for the same day at 11:00 a.m. ET to discuss the results and provide a business update. The company specializes in dermatological treatments, focusing on photodynamic therapy and topical antibiotics. Its licensed products treat actinic keratoses and impetigo.

Positive

• Scheduled conference call for May 13, 2022, indicating planned transparency with investors.

Negative

• None.

News Market Reaction – BFRI

-3.60%

-3.60% Session move

In the trading session that priced this news, BFRI declined 3.60%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before the opening of the U.S. financial markets on Friday, May 13, 2022 and will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.

Conference Call and Webcast Information

Event:	Biofrontera Inc. First Quarter 2022 Financial Results and Business Update Conference Call
Date:	Friday, May 13, 2022
Time:	11:00 a.m. Eastern time
Conference call:	1-877-877-1275 (U.S.) 1-412-858-5202 (international)
Webcast:	Live and 90-day replay webcast are available here and at www.investors.biofrontera-us.com.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Contacts

Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
us-ir@biofrontera.com

LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com

# # #

FAQ

When will Biofrontera report its Q1 2022 financial results?

Biofrontera will report its financial results for Q1 2022 on May 13, 2022.

What time is the Biofrontera conference call on May 13, 2022?

The conference call is scheduled for 11:00 a.m. Eastern time on May 13, 2022.

What is the focus of Biofrontera's products?

Biofrontera specializes in dermatological products, particularly for photodynamic therapy and topical antibiotics.

What conditions do Biofrontera's products treat?

Biofrontera's licensed products treat actinic keratoses and impetigo.

How can I access the webcast of Biofrontera's conference call?

The webcast can be accessed live and on a 90-day replay at Biofrontera's investor relations website.